224 related articles for article (PubMed ID: 24909417)
1. Potentials of polymeric nanoparticle as drug carrier for cancer therapy: with a special reference to pharmacokinetic parameters.
Mukherjee B; Das S; Chakraborty S; Satapathy BS; Das PJ; Mondal L; Hossain CM; Dey NS; Chaudhury A
Curr Drug Metab; 2014; 15(6):565-80. PubMed ID: 24909417
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
[TBL] [Abstract][Full Text] [Related]
3. Potentials and challenges of active targeting at the tumor cells by engineered polymeric nanoparticles.
Mukherjee B; Satapathy BS; Mondal L; Dey NS; Maji R
Curr Pharm Biotechnol; 2013; 14(15):1250-63. PubMed ID: 24910012
[TBL] [Abstract][Full Text] [Related]
4. Nanocarriers for cancer-targeted drug delivery.
Kumari P; Ghosh B; Biswas S
J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle approaches to combating drug resistance.
Moon JH; Moxley JW; Zhang P; Cui H
Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs.
Bayram B; Ozgur A; Tutar L; Tutar Y
Curr Pharm Des; 2017; 23(35):5349-5357. PubMed ID: 28911307
[TBL] [Abstract][Full Text] [Related]
9. The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.
Lee WH; Loo CY; Leong CR; Young PM; Traini D; Rohanizadeh R
Expert Opin Drug Deliv; 2017 Aug; 14(8):937-957. PubMed ID: 27759437
[TBL] [Abstract][Full Text] [Related]
10. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
[TBL] [Abstract][Full Text] [Related]
11. Polymeric Nanoparticles for Brain Drug Delivery - A Review.
Raman S; Mahmood S; Hilles AR; Javed MN; Azmana M; Al-Japairai KAS
Curr Drug Metab; 2020; 21(9):649-660. PubMed ID: 32384025
[TBL] [Abstract][Full Text] [Related]
12. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
Zhong Y; Meng F; Deng C; Zhong Z
Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
[TBL] [Abstract][Full Text] [Related]
13. Reporter nanoparticle that monitors its anticancer efficacy in real time.
Kulkarni A; Rao P; Natarajan S; Goldman A; Sabbisetti VS; Khater Y; Korimerla N; Chandrasekar V; Mashelkar RA; Sengupta S
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2104-13. PubMed ID: 27036008
[TBL] [Abstract][Full Text] [Related]
14. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours.
Cegnar M; Kristl J; Kos J
Expert Opin Biol Ther; 2005 Dec; 5(12):1557-69. PubMed ID: 16318420
[TBL] [Abstract][Full Text] [Related]
15. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy.
Prakash S; Malhotra M; Shao W; Tomaro-Duchesneau C; Abbasi S
Adv Drug Deliv Rev; 2011 Nov; 63(14-15):1340-51. PubMed ID: 21756952
[TBL] [Abstract][Full Text] [Related]
19. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
[TBL] [Abstract][Full Text] [Related]
20. Stimulus-sensitive polymeric nanoparticles and their applications as drug and gene carriers.
Li Y; Gao GH; Lee DS
Adv Healthc Mater; 2013 Mar; 2(3):388-417. PubMed ID: 23184586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
